Deuterium nuclear magnetic resonance (NMR) powder spectra and spin-lattice relaxation times (T(1)) are used to measure the deuterium quadrupolar coupling constants (QCCs) chi(BD) and chi(ND) and to investigate the molecular reorientation of the BD(3) and ND(3) groups in solid deuterated borane monoammoniate, BD(3)NH(3) and BH(3)ND(3), respectively. In the high-temperature, tetragonal, phase (above 225 K) the following Arrhenius parameters are obtained from the temperature-dependent T(1): E(a) = 5.9 +/- 0.5 kJ/mol and tau(infinity) = 1.1 x 10(-)(13) s for BD(3)NH(3); E(a) = 7.3 +/- 0.8 kJ/mol and tau(infinity) = 4.4 x 10(-)(14) s for BH(3)ND(3). In the low-temperature, orthorhombic, phase the following parameters are obtained: E(a) = 26.4 +/- 1.4 kJ/mol and tau(infinity) = 1.2 x 10(-)(17) s for BD(3)NH(3); E(a) = 13.7 +/- 0.9 kJ/mol and tau(infinity) = 5.7 x 10(-)(15) s for BH(3)ND(3). Here tau(infinity) is proportional to the inverse of the usual Arrhenius preexponential factor, A. Deuterium line shape measurements for the low-temperature phase of BD(3)NH(3) yield E(a) = 25 +/- 2 kJ/mol and tau(infinity) = 4.7 x 10(-)(19) s. These dynamic factors indicate that the molecule is probably undergoing whole molecule rotation above the phase transition but the BH(3) and NH(3) groups are undergoing uncorrelated motion in the low-temperature phase. Deuterium quadrupolar coupling constants of 105 +/- 10 and 200 +/- 10 kHz were determined for BD(3)NH(3) and BH(3)ND(3), respectively. Molecular orbital (MO) calculations (CI(SD)/6-31G(d,p)//MP2/6-31G(d,p)) for the isolated molecule yield values of 143 and 255 kHz. MO calculations also show that the deuterium quadrupolar coupling constants chi(BD) and chi(ND) are relatively insensitive to all molecular structural parameters except the B-H and N-H bond lengths, respectively. It is suggested that the large decrease in the QCC on going from the gas phase to the solid state may be due to a slight lengthening of the B-H and N-H bonds, possibly a result of attractive B-H.H-N interactions.
BackgroundThe crude extract of the fruit bearing plant, Physalis peruviana (golden berry), demonstrated anti-hepatoma and anti-inflammatory activities. However, the cellular mechanism involved in this process is still unknown.MethodsHerein, we isolated the main pure compound, 4β-Hydroxywithanolide (4βHWE) derived from golden berries, and investigated its antiproliferative effect on a human lung cancer cell line (H1299) using survival, cell cycle, and apoptosis analyses. An alkaline comet-nuclear extract (NE) assay was used to evaluate the DNA damage due to the drug.ResultsIt was shown that DNA damage was significantly induced by 1, 5, and 10 μg/mL 4βHWE for 2 h in a dose-dependent manner (p < 0.005). A trypan blue exclusion assay showed that the proliferation of cells was inhibited by 4βHWE in both dose- and time-dependent manners (p < 0.05 and 0.001 for 24 and 48 h, respectively). The half maximal inhibitory concentrations (IC50) of 4βHWE in H1299 cells for 24 and 48 h were 0.6 and 0.71 μg/mL, respectively, suggesting it could be a potential therapeutic agent against lung cancer. In a flow cytometric analysis, 4βHWE produced cell cycle perturbation in the form of sub-G1 accumulation and slight arrest at the G2/M phase with 1 μg/mL for 12 and 24 h, respectively. Using flow cytometric and annexin V/propidium iodide immunofluorescence double-staining techniques, these phenomena were proven to be apoptosis and complete G2/M arrest for H1299 cells treated with 5 μg/mL for 24 h.ConclusionsIn this study, we demonstrated that golden berry-derived 4βHWE is a potential DNA-damaging and chemotherapeutic agent against lung cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.